Constrained by the scarcity of published randomized ICI trials with publicly available biomarker datasets, we were only able to validate the predictive value of Ki67+ Tregs in one randomized phase 3 trial in NSCLC. This evidence concerns the gene MKI67 and non-small cell lung carcinoma.